Noveris Announces Resignation Of CEO

(TheNewswire)

Vancouver, British Columbia, March 10, 2026 – TheNewswire — Noveris HealthSciences Inc. (the “Company”) (CSE: NVRS) (FSE: 0NF0) (OTC:MYCOF) announces today that Joshua Bartch has resigned as director,president and chief executive officer of the Company.

The Company has appointed Jason Birmingham, who waspreviously appointed chief strategy officer on February 2, 2026, toassume all three positions formerly held by Mr. Bartch.

The Company would like to thank Mr. Bartch for hisservice and wishes him well in all his future endeavors.

NOVERIS HEALTH SCIENCES INC.

Jason Birmingham

Chief Executive Officer  

Email: jason0612@gmail.com

Phone: +1 (888) 871 - 3936

About Noveris Health Sciences Inc. 

The Company is a biotechnology company developing thenext generation of innovative medications and therapies to addressmental health disorders such as nicotine addiction and posttraumaticstress disorder (PTSD). The core strategy blends advanced technologywith an elaborate infrastructure for drug discovery and development.Noveris’ dedicated multinational team constantly develops new pathsfor breakthrough treatment solutions in areas with considerable unmetneeds. By collaborating with some of the world's leadingspecialists, the Company aspires to responsibly speed up thedevelopment of breakthrough medications to provide patients with saferand more effective treatment solutions. At the same time, Noveris’approach focuses on the next generation of psychedelic medicine bycreating innovative compounds with unmatched therapeutic potentialthrough its clinical trial efforts with worldclass scientific andregulatory expertise.  

NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDERHAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OFTHIS RELEASE.

Copyright (c) 2026 TheNewswire - All rights reserved.